R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.

R&D

Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.

R&D

Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.

R&D

It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.

R&D

Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.

R&D

PurpleLab Managed Services empower clinical development teams to reduce risks and optimise trial execution.